17 April 2026
: Case report 
Cocaine–Levamisole-Associated Vasculopathy Mimicking ANCA-Associated Vasculitis and Presenting With Pulmonary–Renal Syndrome Requiring VV-ECMO Support
Challenging differential diagnosis, Unusual setting of medical care, Rare disease
Zahra Vaezi
ABCDEFG 1*, Afshin Amini ABCDEFG 1
DOI: 10.12659/AJCR.951159
Am J Case Rep 2026; 27:e951159
Table 2 Serial laboratory trends from admission through recovery and long-term follow-up.This table displays the patient’s laboratory data across clinically relevant timepoints, including admission, clinical deterioration, plasmapheresis and ECMO support, post-stabilization, and the 18-month follow-up interval. A treatment-phase column has been added to correlate laboratory fluctuations with major interventions.
| Time point | Hemoglobin (g/dL) | Creatinine (mg/dL) | BUN (mg/dL) | Potassium (mmol/L) | MPO-ANCA (U) | PR3-ANCA (U) | c-ANCA titer | p-ANCA titer |
|---|---|---|---|---|---|---|---|---|
| Admission | 5.8 | 1.50 | 16 | 2.4 | >8.0 | 1.2 | >1: 640 | >1: 640 |
| ICU stay | 8.9 | 1.38 | 16 | 3.4 | – | – | – | – |
| 18 months later | – | 0.80 | 15 | 3.5 | >8.0 | 0.5 | <1: 20 | >1: 640 |